Quince Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period: This Form 8-K reports governance changes dated September 30 and October 1, 2026. It is not a quarterly or annual financial-results filing.
Financial and operating information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or operating-performance figures. It includes no financial guidance or outlook.
Material changes and transaction context
- Directors June Bray, David Lamond, and Christopher Senner submitted conditional resignations. They stated the decisions were not due to disagreements with the company.
- The resignations and four conditional director appointments depend on stockholder approval of three proposals at the October 6, 2026 special meeting. If approved, the changes are expected to take effect two business days after the meeting concludes.
- The proposals cover issuance of common stock upon conversion of Series C preferred stock and exercise of related warrants, as well as exercise of Orphai Therapeutics, LLC options. The filing says the issuance would exceed 20% of outstanding common shares and, with management and board changes, may result in a change of control under Nasdaq rules.
- A separate proposal seeks approval of issuances related to the private placement under Nasdaq’s minimum-price rule. Another would increase authorized common shares from 250 million to 275 million.
- The proposed incoming directors are Catherine Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise. Expected committee roles include Patterson as chair of the Audit and Compensation Committees, Valentine as chair of the Nominating and Corporate Governance Committee, and the other listed committee memberships described in the filing.
- The company intends to enter into its standard indemnification agreements with the incoming directors after their appointments become effective. The filing reports no director appointment arrangements with other persons and no reportable related-party transactions involving the incoming directors.
Risks, contingencies, and investor items to verify
- Whether stockholders approve each of the three proposals at the October 6 special meeting; the board changes are conditional on approval.
- The potential dilution and possible change of control associated with the proposed share issuances and related securities.
- Whether the proposed increase in authorized shares is approved and how the additional authorization may be used.
- The company’s definitive proxy statement, filed August 25, 2026, for details of the proposals and transaction terms; this 8-K does not provide clear values for the number of shares involved or the resulting ownership effects.